- Results from a phase 1 study using KT-474 in the Multiple Ascending Dose portion of data expected on R&D day Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET.
- KT-413 was just given IND clearance from the FDA and a phase 1 study will use the drug to target MYD88 mutant DLBCL.
- KT-333 is a STAT3 protein degrader, which will be used to target patients with liquid and solid tumors.
- Kymera has already established two partnerships for its protein degrader platform technology; The two partnerships in question are with Vertex Pharmaceuticals and Sanofi, both of which could bring in billions of dollars in milestone payments.
For further details see:
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day